@article{de48bf3bcce442aeab57935d9691aa28,
title = "Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial",
abstract = "No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.",
keywords = "Adult, Aged, Aged, 80 and over, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy, Maintenance Chemotherapy, Male, Middle Aged, Obesity/complications, Prognosis, Rituximab/administration & dosage, Survival Analysis, Treatment Outcome",
author = "Alexander Egle and Thomas Melchardt and Petra Obrtl{\'i}kov{\'a} and Luk{\'a}{\v s} Smolej and Tom{\'a}{\v s} Koz{\'a}k and Michael Steurer and Johannes Andel and Sonja Burgstaller and Eva Miku{\v s}kov{\'a} and Liana Gercheva and Thomas N{\"o}sslinger and Tom{\'a}{\v s} Papaj{\'i}k and Miriam Ladick{\'a} and Michael Girschikofsky and Mikul{\'a}{\v s} Hrubi{\v s}ko and Ulrich J{\"a}ger and Daniela Voskova and Martin Pecherstorfer and Eva Kr{\'a}likov{\'a} and Christina Burcoveanu and Emil Spasov and Andreas Petzer and Georgi Mihaylov and Julian Raynov and Horst Oexle and August Zabernigg and Em{\'i}lia Flochov{\'a} and Stanislav Pal{\'a}{\v s}thy and Olga Stehl{\'i}kov{\'a} and Michael Doubek and Petra Altenhofer and Lukas Weiss and Teresa Magnes and Lisa Pleyer and Anton Klingler and Ji{\v r}{\'i} Mayer and Richard Greil",
note = "Funding Information: SB receives support from Roche. AE receives grants and personal fees from Roche. RG receives grants and personal fees from Roche and Takeda, grants from Celgene and Novartis and personal fees from BMS and Amgen. MH receives personal fees from the Czech Lymphoma Study Group, and other support from Roche. TK receives other support from Roche. UJ receives grants and personal fees from Roche. AK receives personal fees from AGMT, Hoffmann‐La Roche, the Central European Society for Anticancer Drug Research and Arbeitsgemeinschaft Internistische Onkologie. JM receives other support from Roche, GlaxoSmithKline and Novartis. HO receives personal fees from Sanofi‐Aventis, Amgen and Celgene. PO receives grants from Roche, nonfinancial support from Janssen and Roche, and personal fees from GlaxoSmithKline and Gilead. AP receives personal fees from Roche. TP receives personal fees from Roche. LS receives personal fees from Abbvie, and personal fees and nonfinancial support from Gilead, Janssen and Roche. MS receives grants and personal fees from Roche. JA, PA, CB, MD, EF, LG, MG, EK, ML, EM, GM, Te.M., Th.M., TN, LP, MP, SP, JR, ES, OS, DV, LW and AZ declare no competing interests. Publisher Copyright: {\textcopyright} 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2019",
month = apr,
doi = "10.1002/cam4.1980",
language = "English",
volume = "8",
pages = "1401--1405",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",
}